Relationship Between Arteriosclerosis Obliterans and Serum Level of Eicosapentaenoic Acid as Prospective Interventional Study

Relationship Between Arteriosclerosis Obliterans and Serum Level of Eicosapentaenoic Acid as Prospective Interventional Study - EPA Prospective (EPAP)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011869

Enrollment

Registered

2013-09-26

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arteriosclerosis Obliterans

Interventions

cilostazol 200 mg/day 6 months cilostazol 200 mg /day eicosapentaenoic acid 1800 mg/day 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASO patients with intermittent claudication

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
6 minutes walking test	—

Secondary

Measure	Time frame
Fontain's class, ABPI, SPP, ammonia PET, incidence of AMI, stroke and cardiovascular death	—

Countries

Japan

Contacts

Public ContactSecretariat

National Center for Global Health and Medicine Cardiovascular Surgery

shinzou.gimu@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026